# Marker Therapeutics, Inc.: overview MRKR · Nasdaq · CIK 1094038 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mrkr.md) · [Financials](/companies/mrkr/financials.md) · [Filings](/companies/mrkr/filings.md) · [Insiders](/companies/mrkr/insiders.md) Latest reported revenue: [$751.7k](/filings/0001104659-26-062763.md) for Q1 FY2026, three months to 2026-03-31, from the 10-Q filed May 15, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001104659-26-062763). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,926](/filings/0001104659-25-111502.md) | [2,252 d](/filings/0001104659-26-031274.md) | [349](/filings/0001104659-26-062763.md) | [861](/filings/0001410578-25-001826.md) | [1,233](/filings/0001104659-25-111502.md) | [1,103 d](/filings/0001104659-26-031274.md) | [752](/filings/0001104659-26-062763.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(124.6%)](/filings/0001104659-25-111502.md) | [(171.5%) d](/filings/0001104659-26-031274.md) | [(1420.1%)](/filings/0001104659-26-062763.md) | [(594.8%)](/filings/0001104659-26-097262.md) | [(173.3%)](/filings/0001104659-25-111502.md) | [(170.7%) d](/filings/0001104659-26-031274.md) | [(541.8%)](/filings/0001104659-26-062763.md) | not reported | | Net margin | % | [(119.8%)](/filings/0001104659-25-111502.md) | [(170.4%) d](/filings/0001104659-26-031274.md) | [(1273.6%)](/filings/0001104659-26-062763.md) | [(466.3%)](/filings/0001104659-26-097262.md) | [(162.1%)](/filings/0001104659-25-111502.md) | [(154.4%) d](/filings/0001104659-26-031274.md) | [(423.0%)](/filings/0001104659-26-062763.md) | not reported | | Diluted EPS | $ per share | [(0.26)](/filings/0001104659-25-111502.md) | not reported | [(0.40)](/filings/0001104659-26-062763.md) | [(0.29)](/filings/0001104659-26-097262.md) | [(0.12)](/filings/0001104659-25-111502.md) | not reported | [(0.16)](/filings/0001104659-26-062763.md) | [(0.09)](/filings/0001104659-26-097262.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001410578-22-000418.md) | [3,514](/filings/0001410578-24-000297.md) | [3,311](/filings/0001410578-25-000549.md) | [6,591](/filings/0001104659-26-031274.md) | [3,547](/filings/0001104659-26-031274.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(563.3%)](/filings/0001410578-24-000297.md) | [(440.4%)](/filings/0001410578-25-000549.md) | [(168.7%)](/filings/0001104659-26-031274.md) | [(363.5%)](/filings/0001104659-26-031274.md) | | Net margin | % | not reported | [(851.9%)](/filings/0001410578-24-000297.md) | [(248.8%)](/filings/0001410578-25-000549.md) | [(162.8%)](/filings/0001104659-26-031274.md) | [(343.0%)](/filings/0001104659-26-031274.md) | | Diluted EPS | $ per share | [(5.47)](/filings/0001410578-23-000324.md) | [(3.58)](/filings/0001410578-24-000297.md) | [(0.94)](/filings/0001410578-25-000549.md) | [(1.19)](/filings/0001104659-26-031274.md) | [(0.79)](/filings/0001104659-26-031274.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mrkr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $2.4m | 1,625,678 | | Unchanged | | [Blue Owl Capital Holdings LP](/funds/1858703.md) | 2026-06-30 | $814.7k | 554,250 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $626.5k | 426,169 | | Added +36,850 | | [Aisling Capital Management LP](/funds/1766721.md) | 2026-06-30 | $478.3k | 325,370 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $366.7k | 249,423 | | Added +74,129 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $205.6k | 139,816 | | Reduced −21,094 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $165.6k | 112,649 | | Added +19,528 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $128.3k | 87,269 | | Unchanged | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $122.2k | 83,147 | | Added +100 | | [Concurrent Investment Advisors, LLC](/funds/2001015.md) | 2026-06-30 | $99.9k | 67,963 | | New +67,963 | ## Recent filings [All 700 filings](/companies/mrkr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 11:12 ET | [8-K](/filings/0001104659-26-116720.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-116720 | | 2026-08-14 | 20:35 ET | [10-Q](/filings/0001104659-26-097262.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097262 | | 2026-05-15 | 21:00 ET | [10-Q](/filings/0001104659-26-062763.md) | Quarterly report, period 2026-03-31 | 0001104659-26-062763 | | 2026-05-04 | 20:30 ET | [8-K](/filings/0001104659-26-054940.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-054940 | | 2026-03-20 | 20:05 ET | [DEF 14A](/filings/0001104659-26-032694.md) | Proxy statement, period 2026-05-01 | 0001104659-26-032694 | | 2026-03-19 | 21:36 ET | [8-K](/filings/0001104659-26-031309.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-031309 | | 2026-03-18 | 21:26 ET | [10-K](/filings/0001104659-26-031274.md) | Annual report, period 2025-12-31 | 0001104659-26-031274 | | 2026-02-09 | 21:06 ET | [8-K](/filings/0001104659-26-012063.md) | 5.08 Item not in the standard list; 9.01 Financial statements and exhibits | 0001104659-26-012063 | | 2025-11-17 | 21:22 ET | [SCHEDULE 13D/A](/filings/0001072613-25-000858.md) | Ownership report, active investor, amended | 0001072613-25-000858 | | 2025-11-14 | 12:20 ET | [8-K](/filings/0001104659-25-111940.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-111940 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-031274.md), filed Mar 18, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1094038 - Tickers: MRKR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.